BridgeBio's heart drug launch gets off to a fast start [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Shares of BridgeBio Pharma ticked up on Thursday after the company reported early but encouraging signs of demand for a drug it's just begun selling for a deadly heart condition. According to fresh earnings results , 516 doctors have written 1,028 unique prescriptions for the drug, sold as Attruby, since it was approved on Nov. 22 as a treatment for transthyretin amyloidosis with cardiomyopathy. While those prescriptions have yet to translate to significant sales for BridgeBio — it recorded $2.9 million in net product revenue through the end of 2024 — they've more than doubled since an earlier update from the company in January “I am very encouraged by the strength of the Attruby launch, with prescriptions being successfully filled across all patient types,” said Matt Outten, BridgeBio's chief commercial officer, in a statement. The update lifted BridgeBio shares about 5% in early trading Thursday. The company's stock price has climbed more than 30% since the beginning of the y
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.MarketBeat
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.MarketBeat
- What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.MarketBeat
- BridgeBio to Participate in December Investor ConferencesGlobeNewswire
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- BBIO's page on the SEC website